ESR1 and breast carcinoma: Adjuvant HT alone has therefore been incorporated into the National Comprehensive Cancer Networks (NCCN) guidelines as a category 1 recommendation for women 70 years or older with early stage estrogen‐receptor positive breast cancer.7